OSAKA -- Japanese drugmaker Shionogi will review how it sources raw materials for its oral COVID-19 drug Xocova in an attempt to shift away from a heavy reliance on China, President and CEO Isao Teshirogi said in an interview with Nikkei.
Pharmaceuticals
Shionogi seeks to break away from China for COVID drug materials
Japanese company to revamp supply chain, turns to India and Japan for chemicals
Shionogi President and CEO Isao Teshirogi said the company is looking to expand production of Xocova to 30 million doses a year. (Photo by Atsushi Ooka)
Read Next
Latest on Pharmaceuticals
